Comparison of methods for the quantification of cell-free DNA isolated from cell culture supernatant:
TL;DR: Five commonly used cell-free DNA quantification methods are compared, including quantitative polymerase chain reaction, Qubit Double-Stranded DNA high Sensitivity assay, Quant-iT PicoGreen Assay, Bioanalyzer High Sensitivity DNA assay, and NanoDrop Onec, and an interpretation of theoretical values enables the calculation of optimal conditions for several important preanalytical steps.
read more
Abstract: Gaining a better understanding of the biological properties of cell-free DNA constitutes an important step in the development of clinically meaningful cell-free DNA-based tests. Since the in vivo characterization of cell-free DNA is complicated by the immense heterogeneity of blood samples, an increasing number of in vitro cell culture experiments, which offer a greater level of control, are being conducted. However, cell culture studies are currently faced with three notable caveats. First, the concentration of cell-free DNA in vitro is relatively low. Second, the median amount and size of cell-free DNA in culture medium varies greatly between cell types. Third, the amount and size of cell-free DNA in the culture medium of a single cell line fluctuates over time. Although these are interesting findings, it can also be a great source of experimental confusion and emphasizes the importance of method optimization and standardization. Therefore, in this study, we compared five commonly used cell-free DNA quantification methods, including quantitative polymerase chain reaction, Qubit Double-Stranded DNA High Sensitivity assay, Quant-iT PicoGreen Assay, Bioanalyzer High Sensitivity DNA assay, and NanoDrop Onec. Analysis of the resulting data, along with an interpretation of theoretical values (i.e. the theoretical detection and quantification limits of the respective methods), enables the calculation of optimal conditions for several important preanalytical steps pertaining to each quantification method and different cell types, including the (1) time-point at which culture medium should be collected for cell-free DNA extraction, (2) amount of cell culture supernatant from which to isolate cell-free DNA, (3) volume of elution buffer, and (4) volume of cell-free DNA sample to use for quantification.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Circulating DNA fragmentomics and cancer screening
TL;DR: Fragmentomics can be regarded as a strategy for characterizing cancer within individuals and offers an alternative or a synergistic supplement to mutation searches, methylation, or nucleosome positioning as discussed by the authors .
56
Technical and Methodological Aspects of Cell-Free Nucleic Acids Analyzes
Zuzana Pös,Ondrej Pös,Jakub Styk,Angelika Mocova,Angelika Mocova,Lucia Strieskova,Jaroslav Budis,Ludevit Kadasi,Ludevit Kadasi,Jan Radvanszky,Jan Radvanszky,Tomáš Szemes +11 more
TL;DR: An overview of the available literature and products commercialized for cfNAs processing is prepared in an attempt to summarize the benefits and limitations of the currently available approaches, devices, consumables, and protocols, together with various factors influencing the workflow, its processes, and outcomes.
42
Liquid biopsy with cell free DNA: new horizons for prostate cancer
TL;DR: A multiparametric approach combining the analysis of total cfDNA (both ssDNA and dsDNA), cfDNA fragment length, and specific genetic mutations (ctDNA assessment) is required for optimal future applications of liquid biopsy.
40
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation.
Jonathan Dao,Patrick J. Conway,Baskar Subramani,Devi Meyyappan,Sammy Russell,Daruka Mahadevan +5 more
TL;DR: Measuring total cfDNA could be a cost-effective, viable prognostic marker, but various factors do not favor it as a monitoring tool during chemotherapy, and the lack of standardization means that it is difficult to move forward with large-scale clinical validation studies currently.
31
Concentration of cell-free DNA in different tumor types.
TL;DR: The present review aimed to synthesize the available data oncfDNA concentration in the cancer patient’s blood as well as pre-analytical, analytical, and biological factors, which interfere with cfDNA concentration.
26
References
The emerging role of cell-free DNA as a molecular marker for cancer management.
TL;DR: Recent advancements are explored and the current gaps in knowledge concerning each point of contact between cfDNA analysis and the different stages of cancer management are highlighted.
499
Non-invasive prenatal measurement of the fetal genome
H. Christina Fan,Wei Gu,Jianbin Wang,Yair J. Blumenfeld,Yasser Y. El-Sayed,Stephen R. Quake,Stephen R. Quake +6 more
TL;DR: It is demonstrated that it is possible to non-invasively sequence the entire prenatal genome and molecular counting of parental haplotypes in maternal plasma by shotgun sequencing of maternal plasma DNA allows the inherited fetal genome to be deciphered non- invasively.
Inferring expressed genes by whole-genome sequencing of plasma DNA
Peter Ulz,Gerhard G. Thallinger,Martina Auer,Ricarda Graf,Karl Kashofer,Stephan W Jahn,Luca Abete,Gunda Pristauz,Edgar Petru,Jochen B. Geigl,Ellen Heitzer,Michael R. Speicher +11 more
TL;DR: It is found that the plasma DNA read depth patterns from healthy donors reflected the expression signature of hematopoietic cells, and in patients with cancer having metastatic disease, expressed cancer driver genes in regions with somatic copy number gains with high accuracy were classified.
The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature
TL;DR: This review presents an extensive compilation of the putative origins ofcfDNA and contrasts the contributions of cellular breakdown processes with active mechanisms for the release of cfDNA into the extracellular environment.
270
Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA
Hai Zemmour,David Planer,Judith Magenheim,Joshua Moss,Daniel Neiman,Dan Gilon,Amit Korach,Benjamin Glaser,Ruth Shemer,Giora Landesberg,Yuval Dor +10 more
TL;DR: It is shown that cardiomyocyte-specific methylation patterns of circulating cell-free DNA may serve as a biomarker of cardiac cell death in infarcted and septic patients.